Gilead’s Trodelvy fails to extend survival in lung cancer study, prompting selloff

BioNTech and DualityBio initiate Phase 3 Trial for BNT323/DB-1303 in Metastatic Breast Cancer

RC48-ADC combos show efficacy in HER2+ and HER2-Low Breast Cancers

Oxford BioTherapeutics doses first patient with OBT076 in Phase 1b trial for Head and Neck...